An Extension Study for Patients Previously Enrolled in Studies With Pelabresib
An Open-Label, Multicenter, Extension Study for Patients Previously Enrolled in Studies With Pelabresib
Novartis Pharmaceuticals
50 participants
Aug 13, 2024
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to evaluate the long-term safety and the clinical benefit of pelabresib in patients with hematological and/or solid tumor indications or advanced malignancies. Additionally, participants previously enrolled in studies with pelabresib who received placebo or participants who discontinued pelabresib (for any other reason than participating in this extension study), may be enrolled in this extension study to evaluate the survival and leukemia-free survival (for patients with hematological malignancies) or only the Survival Follow-up (for all the other patients).
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Small molecule inhibitor of bromodomain and extraterminal (BET) protein
Locations(15)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06401356